Daily Cardiology Research Analysis
Analyzed 166 papers and selected 3 impactful papers.
Summary
A multicenter randomized trial shows lumenless leads outperform stylet-driven leads for left bundle branch pacing, reducing loss of capture and acute lead damage. Mechanistic work identifies epicardial fat–resident macrophages, especially Lyve1+ subsets, as key drivers of atrial cardiomyopathy, while a cardio-oncology study demonstrates that the MEK inhibitor trametinib induces mitochondrial injury and innate immune activation in the mouse heart.
Research Themes
- Physiologic pacing and device optimization
- Atrial cardiomyopathy and epicardial adipose–immune crosstalk
- Cardio-oncology and kinase inhibitor cardiotoxicity
Selected Articles
1. Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes: LEAD-LBBP Randomized Clinical Trial.
In a multicenter randomized trial of 226 patients, stylet-driven leads led to higher 12-month loss of left bundle capture (22% vs 10%), lower acute LBBP success (85% vs 96%), and more acute lead damage (10% vs 3%) compared with lumenless leads, with no differences in clinical outcomes over 12 months. These data support preferring lumenless leads to improve procedural success and durability of conduction system capture.
Impact: This RCT provides direct, practice-informing evidence on lead selection for left bundle branch pacing, a rapidly expanding physiological pacing strategy.
Clinical Implications: Prefer lumenless leads for LBBP to reduce loss of left bundle capture and acute lead damage, potentially decreasing re-interventions. Procedural planning and inventory should reflect these findings.
Key Findings
- Loss of left bundle capture at 12 months: 22% with stylet-driven leads vs 10% with lumenless leads (P=0.011; HR 2.72, 95% CI 1.34-5.54).
- Acute LBBP success was lower with stylet-driven leads (85% vs 96%; P=0.007).
- Acute lead damage occurred more often with stylet-driven leads (10% vs 3%; P=0.027; OR 3.95, 95% CI 1.07-14.58).
Methodological Strengths
- Multicenter, blind-adjudicated randomized clinical trial with prespecified endpoints.
- Robust comparative analysis with clinically meaningful device outcomes.
Limitations
- Sample size modest and not powered for differences in hard clinical outcomes.
- Follow-up limited to 12 months; long-term capture durability beyond a year remains unknown.
Future Directions: Longer-term, larger RCTs should assess clinical endpoints (HF hospitalization, mortality), cost-effectiveness, and performance across operators and anatomies.
BACKGROUND: Stylet-driven leads (SDLs) are associated with increased loss of left bundle branch capture (LLC) and lead damage during implantation in left bundle branch pacing (LBBP). OBJECTIVES: This study examined the differences in LLC and pacing outcomes in LBBP recipients randomized to receive lumenless leads (LLLs) or SDLs. METHODS: LEAD-LBBP (Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes: The LEAD_LBBP Randomized Clinical Trial) was a multicenter, blind-adjudicated, randomized clinical trial of LBBP recipients with block randomization in a 1:1 ratio to LLL or SDL. The primary endpoint was the incidence of LLC in both groups. Secondary endpoints included acute LBBP success, acute lead damage requiring a new lead, pacing parameters, complications, and clinical outcomes (new-onset atrial fibrillation [AF], heart failure hospitalization, and all-cause mortality). RESULTS: Of 226 patients (mean age 74.9 ± 9.6 years, 97 [44%] female), 113 were randomized to the LLL group and 113 to the SDL group. The primary endpoint of LLC at 12 months occurred in 36 (16%) patients, more frequently with SDLs compared with LLLs (22% vs 10%; P = 0.011), with a 2.7 times increased risk (HR: 2.72; 95% CI: 1.34-5.54; P = 0.006). SDLs were also associated with a lower acute LBBP success (96% LLL vs 85% SDL; P = 0.007) and a higher incidence of acute lead damage (10% SDL vs 3% LLL; P = 0.027; OR: 3.95; 95% CI: 1.07-14.58). Pacing parameters, overall complications, and clinical outcomes were comparable between the SDL and LLL groups (P > 0.05). CONCLUSIONS: Among LBBP recipients, SDL compared with LLL resulted in a higher incidence of LLC during follow-up, lower acute LBBP procedural success, and greater acute lead damage during implantation. These findings have significant implications for lead selection in LBBP.(Comparison of Pacing Lead Design on Left Bundle Branch Pacing Outcomes: The LEAD_LBBP Randomized Clinical Trial [LEAD-LBBP]; NCT06318130).
2. Epicardial Fat Drives Macrophage Response in Atrial Cardiomyopathy.
Spatial transcriptomics in human atria and single-cell RNA-seq in a murine obesity model identify epicardial fat–resident macrophage subsets, including Lyve1+ populations, that are closely linked to atrial adiposity and atrial cardiomyopathy. These data position macrophage–epicardial fat interactions as central drivers of atrial substrate remodeling.
Impact: Provides a mechanistic link between epicardial adipose tissue inflammation and atrial cardiomyopathy, offering new immunometabolic targets for AF substrate modification.
Clinical Implications: Supports aggressive management of adiposity and inflammation in AF risk, and motivates development of therapies targeting epicardial fat–resident macrophages to modify the atrial substrate.
Key Findings
- Spatial gene expression mapping of human atria identified macrophage subpopulations predominantly localized to epicardial fat.
- In obese murine atrial cardiomyopathy, macrophage recruitment correlated with atrial adiposity.
- Single-cell RNA sequencing highlighted Lyve1+ macrophage subsets implicated in atrial adipose-driven remodeling.
Methodological Strengths
- Integration of human spatial transcriptomics with murine single-cell RNA-seq across models.
- Clear tissue-compartment resolution implicating epicardial fat–resident immune niches.
Limitations
- Predominantly preclinical and descriptive; lacks interventional validation in humans.
- Causality and translatability of specific macrophage subsets to clinical AF remain to be proven.
Future Directions: Test macrophage-targeted or epicardial fat–modifying interventions in translational models and evaluate circulating/imaging biomarkers reflecting atrial immune–adipose activity.
BACKGROUND: Inflammation is associated with atrial fibrillation, but its precise impact on the long-term progression of the atrial fibrillation substrate, also called atrial cardiomyopathy, remains debated. METHODS AND RESULTS: Here, using spatial gene expression analysis, macrophage subpopulations mainly confined to the epicardial fat tissue were identified in the human atria. In a mouse model of obesity and atrial cardiomyopathy, macrophage recruitment was associated with atrial adiposity. Single-cell RNA sequencing allowed the identification of Lyve1 CONCLUSIONS: These data highlight the pivotal role of macrophages in atrial adiposity, in particular that of Lyve1
3. The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.
In murine hearts, trametinib exposure led to mitochondrial injury and activation of innate immune pathways while suppressing ERK1/2 signaling, delineating a mechanistic basis for MEK inhibitor cardiotoxicity. These findings broaden cardio-oncology understanding of kinase inhibitor effects on cardiac bioenergetics and immune signaling.
Impact: Reveals mitochondrial and innate immune mechanisms underlying MEK inhibitor cardiotoxicity, informing surveillance strategies and potential mitigation in patients receiving trametinib.
Clinical Implications: Cardio-oncology programs should consider mitochondrial injury and inflammatory signaling as surveillance targets (biomarkers, imaging) during trametinib therapy and evaluate cardioprotective co-therapies in high-risk patients.
Key Findings
- Trametinib suppresses ERK1/2 activation but induces mitochondrial injury in the mouse heart.
- Innate immune responses are triggered in cardiac tissue following trametinib exposure.
- Findings delineate mechanistic pathways for MEK inhibitor–associated cardiotoxicity.
Methodological Strengths
- In vivo mechanistic assessment in a controlled murine model.
- Pathway-level interrogation linking kinase inhibition to mitochondrial and immune effects.
Limitations
- Preclinical mouse data; dose–exposure equivalence to human therapy requires caution.
- Limited human validation; translational biomarkers were not established.
Future Directions: Define exposure–response relationships, identify translational biomarkers of mitochondrial injury/innate activation, and test cardioprotective strategies alongside MEK inhibitors.
Trametinib (Trm) is a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor that potently and persistently abrogates extracellular signal-regulated kinase 1/2 activation. Trm initially was used to treat BRAF Val